Pegbio publishes 2025 annual report

• PegBio annual report for 2025 highlighted transition toward commercialization following China marketing clearance for core GLP-1 drug PB-119 (Visepegenatide) in November 2025.
• Commercial launch preparations continued across manufacturing, supply chain, market access, patient support, and academic promotion, with first-half 2026 targeted for initial sales.
• Company maintained focus on metabolic diseases, with plans to expand into adjacent chronic disease areas such as cardiovascular and gastrointestinal conditions.
• Pipeline progress continued, with PB-718 advanced in obesity and MASH development and multiple earlier-stage metabolic programs positioned for IND submissions or trial starts in 2026.
• PegBio reported no product sales revenue to date, with operating performance still shaped mainly by R&D and administrative spending.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12131044), on April 28, 2026, and is solely responsible for the information contained therein.